本帖最后由 老马 于 2013-3-13 13:43 编辑
9 Q+ ^7 @( X- @1 K0 `( ?8 _ `2 ?6 o0 s6 N: P
健择（吉西他滨）+顺铂+阿瓦斯汀( m% d0 U% P% q" q1 [* w4 o/ C) W" s0 _
Gemzar +Cisplatin + Avastin
# b% A" m, w* g8 D: K2 N8 Dhttp://annonc.oxfordjournals.org/content/21/9/1804.full
7 d2 w; @2 ?8 u0 O2 O1 d# E pOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ n* Y# d) E. s" @* @6 pPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 0 x" u& x' }$ D
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
! s: d: Y4 i. Z. z! b9 O" n
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 639)
# p: \# Y6 v# T y" m6 B: r
华为网盘附件：: K& D7 ]. X' y$ a! n
【华为网盘】ava.JPG
: p& p i; _- W) z1 I! Y |
显身卡
